These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36321745)

  • 1. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
    Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
    Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
    Yilmaz M; Kantarjian H; Wang X; Khoury JD; Ravandi F; Jorgensen J; Short NJ; Loghavi S; Cortes J; Garcia-Manero G; Kadia T; Sasaki K; Konopleva M; Takahashi K; Wierda W; Jain N; Verstovsek S; Estrov Z; Bose P; Pierce S; Garris R; O'Brien S; Jabbour E
    Am J Hematol; 2020 Feb; 95(2):144-150. PubMed ID: 31682008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.
    Zheng Y; Pan L; Li J; Feng X; Li C; Zheng M; Mai H; Yang L; He Y; He X; Xu H; Wen H; Le S
    BMC Cancer; 2024 Jan; 24(1):46. PubMed ID: 38195455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
    Ferrari LC; Rivas MM; Navickas AB; Dick H; Mela Osorio MJ; Agamennoni L; Rey IH; Carnelutto NE; Cazap N; Castro MB; Aranguren PN; Fischman LA; Yupanki ML; Milone JH; Fernández II; Moirano MM; Belli CB;
    Ann Hematol; 2023 May; 102(5):1087-1097. PubMed ID: 36892593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
    Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
    Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience.
    Arunachalam AK; Selvarajan S; Mani T; Janet NB; Maddali M; Lionel SA; Kulkarni U; Korula A; Aboobacker FN; Abraham A; George B; Balasubramanian P; Mathews V
    Cytometry B Clin Cytom; 2023 Nov; 104(6):440-452. PubMed ID: 37555390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].
    Wei T; Chen XJ; Zhang LY; Zhang AL; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1279-1285. PubMed ID: 33327998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Yan N; Wang ZL; Wang XJ; Gale RP; Zhou YL; Zhao MY; Wu LX; Liao MY; Yang J; Wang CY; Zhu JH; Jiang H; Jiang Q; Liu YR; Chang YJ; Xu LP; Zhang XH; Ma TH; Huang XJ; Ruan GR
    Cancer Lett; 2024 Aug; 598():217104. PubMed ID: 38969163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
    Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
    Front Oncol; 2020; 10():577. PubMed ID: 32391267
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
    Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
    Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
    Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.